Recursion (RXRX) director Zavain Dar granted 88,424 restricted stock units

Rhea-AI Filing Summary

Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.

RECURSION PHARMACEUTICALS director Zavain Dar received an equity grant. He was awarded 88,424 shares of Class A Common Stock in the form of restricted stock units for board service, at no cash cost. These RSUs vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholder meeting, subject to continued service, bringing his direct holdings to 235,655 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dar Zavain

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	88,424	$0.00	--

Holdings After Transaction: Class A Common Stock — 235,655 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 88,424 shares Holdings after transaction: 235,655 shares Grant price per share: $0.0000 per share +1 more

4 metrics

RSUs granted 88,424 shares Restricted stock unit award on June 17, 2026

Holdings after transaction 235,655 shares Class A Common Stock held directly after grant

Grant price per share $0.0000 per share Reported transaction price for RSU grant

Vesting date trigger June 17, 2027 Earlier of this date or day before 2027 annual meeting

Key Terms

restricted stock units, Outside Director Compensation Policy, Annual Meeting of Stockholders

3 terms

restricted stock units financial

"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Outside Director Compensation Policy financial

"automatically granted pursuant to the Issuer's Outside Director Compensation Policy."

Annual Meeting of Stockholders regulatory

"will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dar Zavain

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/17/2026		A(1)		88,424	A	$0	235,655	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did RXRX director Zavain Dar receive in this Form 4 filing?

Zavain Dar received 88,424 shares of Class A Common Stock in the form of restricted stock units. The grant was made under Recursion Pharmaceuticals’ Outside Director Compensation Policy as part of his compensation for serving on the board.

When do Zavain Dar’s new RXRX restricted stock units vest?

The restricted stock units vest on the earlier of June 17, 2027, or the day before Recursion Pharmaceuticals’ 2027 Annual Meeting of Stockholders. Vesting is conditioned on Dar continuing to provide service to the company through that date.

How many RXRX shares does Zavain Dar hold after this transaction?

After the grant, Zavain Dar directly holds 235,655 shares of Recursion Pharmaceuticals Class A Common Stock. This total includes the 88,424 restricted stock units reported in the filing that are subject to future vesting conditions.

Was Zavain Dar’s RXRX equity grant a market purchase or sale?

The transaction was a grant of restricted stock units, not a market purchase or sale. It was automatically awarded under the company’s Outside Director Compensation Policy, with no price paid per share reported in the Form 4.

What is the nature of the RXRX equity reported for Zavain Dar?

The equity consists of restricted stock units that convert into Class A Common Stock upon vesting. These units are part of standard outside director compensation and are subject to vesting tied to continued service on the Recursion Pharmaceuticals board.